Clinical trials: Enoxaparin
Pregnancy, High Risk, Anticoagulants
Anticoagulation Profile in Pregnant Women Treated With Three Times a Day of Low Molecular Weight Heparin (LMWH)
Pregnancy is associated with a increased risk of developing blood clots. There is nearly a 5 times greater risk of developing a blood clot in pregnancy.
- Trial name
- NCT04861103
- Testing
- Lovenox
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University of California, Irvine
Atrial Fibrillation
Assessment of Cardioversion Using Transesophageal Echocardiography II (ACUTE II)
SPECIFIC AIM: To test the safety and feasibility of using low molecular weight heparin (LMWH, enoxaparin sodium; Lovenox, Sanofi-Aventis) in lieu of unfractionated heparin (UFH) as antithrombotic therapy for patients in atrial…
- Trial name
- NCT00289042
- Testing
- Enoxaparin
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- The Cleveland Clinic
Fetal Demise, Fetal Growth Restriction
Dose Adjusting Enoxaparin Thromboprophylaxis Dosage According to Anti-factor Xa Plasma Levels Improve Pregnancy Outcome
The risk of venous thromboembolism increases in pregnancy. Thrombophilia whether genetic or acquired, is a hypercoagulable disorder that may increase the risk of venous thromboembolic events.
- Conditions
- Fetal Demise, Fetal Growth Restriction, Preeclampsia, Abruptio Placentae
- Trial name
- NCT01068795
- Testing
- enoxaparin
- Where
- Israel
- Volunteers
- 144 people
- Sponsor
- HaEmek Medical Center, Israel
Deep Vein Thrombosis of Lower Limb, Pulmonary Embolism (PE)
Deep Vein Thrombosis (DVT) Prevention in Total Hip Arthroplasty: Continuous Enhanced Circulation Therapy (CECT) Versus Low Molecular Weight Heparin (LMWH)
Evaluation of the safety and effectiveness of ActiveCare+ CECT device +/- baby dose aspirin (81 mg QD) for lowering the potential risk for bleeding and of DVT during and after THA surgery in comparison with LMWH.
- Conditions
- Deep Vein Thrombosis of Lower Limb, Pulmonary Embolism (PE), Bleeding
- Trial name
- SAFE (NCT00358735)
- Testing
- ActiveCare CECT device, Enoxaparin
- Where
- 9 sites in United States
- Volunteers
- 411 people
- Sponsor
- Medical Compression Systems
Venous Thromboembolic Event
Utilizing Anti-Factor Xa as a Predictive Tool for Optimizing Outcome in Burn Patients' Management
This study aims to compare the efficacy of anti-Xa based versus weight-based enoxaparin dosing and to evaluate anti-Xa levels as a predictive tool for clinical outcomes in burn patients
- Trial name
- NCT07464808
- Testing
- follow up venous thrombo embolic events with routine clexan dose modification guided by anti factor 10 assay, follow up venous thromboembolic events with no routine clexan dosage modification and no usage of anti factor 10 assay
- Where
- Egypt
- Volunteers
- 25 people
- Sponsor
- Ain Shams University
Healthy
Pharmacodynamics Study of Enoxalow Compared to Clexane in Healthy Subjects After Subcutaneous Single Dose
The hypothesis of this trial is that the test drug (Enoxalow® - T) pharmacodynamics parameters are similar to the comparator drug (Clexane® - C) in healthy subjects following administration of single subcutaneous dose.
- Trial name
- NCT01692158
- Testing
- Heparin, Low-Molecular-Weight
- Where
- Brazil
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Azidus Brasil
Covid19, Thrombosis
Enoxaparin at Prophylactic or Therapeutic Doses in COVID-19
SINGLE CENTER PHASE III INTERVENTIONAL RANDOMIZED CONTROLLED TRIAL comparing efficacy and safety of enoxaparin at prophylactic dose (standard treatment) and enoxaparin at therapeutic dose (OFF-LABEL treatment) in 300 COVID-19…
- Trial name
- EMOS-COVID (NCT04646655)
- Testing
- Enoxaparin
- Where
- Italy
- Volunteers
- 142 people
- Sponsor
- ASST Fatebenefratelli Sacco
COVID-19
Anticoagulation in Critically Ill Patients With COVID-19 (The IMPACT Trial)
The purpose of this study is to determine if therapeutic dose anticoagulation (experimental group) improves 30-day mortality in participants with COVID-19 compared to those patients receiving the intermediate dose prophylaxis…
- Trial name
- IMPACT (NCT04406389)
- Testing
- Enoxaparin sodium, Unfractionated heparin, Fondapariniux
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- Weill Medical College of Cornell University
Cancer, Stroke
Anticoagulation in Cancer Related Stroke
Purpose: Cancer associated intravascular coagulopathy is the primary mechanism of cancer-related stroke, particularly in those without conventional stroke etiologies.
- Trial name
- OASIS-CANCER (NCT02743052)
- Testing
- Anticoagulation treatment.
- Where
- South Korea
- Volunteers
- 400 people
- Sponsor
- Samsung Medical Center
Alive and Viable Births
Prevention of Unexplained Recurrent Abortion by Enoxaparine
Standard investigations fail to reveal any apparent cause in 50% of the cases of recurrent spontaneous abortion. Prothrombotic mechanisms were initially evoked.
- Trial name
- PREFIX (NCT00740545)
- Testing
- enoxaparine 40 mg daily
- Where
- 7 sites in France
- Volunteers
- 258 people
- Sponsor
- University Hospital, Brest
Arthroplasty, Replacement, Knee, Thromboembolism
Dabigatran Etexilate vs Enoxaparin in Prevention of Venous Thromboembolism (VTE) Post Total Knee Replacement
To determine the comparative efficacy and safety of two different doses (75mg day 1 followed by 150 mg day 2-completion, and 110 mg day 1 followed by 220 mg day 2-completion) of dabigatran administered orally (capsules), compared…
- Trial name
- NCT00152971
- Testing
- Dabigatran Dose 1 - day 2 to completion, Dabigatran Dose 1 - day 1, Dabigatran Dose 2 - day 2 to completion
- Where
- 94 sites in United States, Canada and 2 more
- Volunteers
- 2,615 people
- Sponsor
- Boehringer Ingelheim
Healthy Participants
A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Participants
The purpose of this study is to characterize andexanet posology and interaction between andexanet and enoxaparin post infusion in healthy participants.
- Trial name
- NCT07312851
- Testing
- Andexanet alfa, Rivaroxaban, Apixaban
- Where
- 2 sites in Germany, United Kingdom
- Volunteers
- 191 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Hemorrhagic Stroke, Venous Thromboembolism
PREvention of VENous Thromboembolism In Hemorrhagic Stroke Patients
Patients with cerebral hemorrhage (ICH) have a high risk of venous thromboembolism. Intermittent pneumatic compression combined with elastic stockings have been shown to be superior to elastic stockings alone in reducing the rate…
- Conditions
- Hemorrhagic Stroke, Venous Thromboembolism, Deep Venous Thrombosis
- Trial name
- PREVENTIHS (NCT01573169)
- Testing
- Enoxaparin, Graduated compression stockings and/or intermittent pneumatic compression and/or early mobilization
- Where
- Italy
- Volunteers
- 73 people
- Sponsor
- University Of Perugia
Acute Ischemic Stroke
PREVAIL: PREvention of VTE After Acute Ischemic Stroke With LMWH Enoxaparin ( - VTE: Venous Thromboembolism - LMWH: Low Molecular Weight Heparin)
Primary objective: To demonstrate superiority of enoxaparin 40 mg sc qd in the prevention of VTE compared to UFH (unfractionated heparin) 5000 U sc q12 hours given for 10 ± 4 days following acute ischemic stroke.
- Trial name
- NCT00077805
- Testing
- Enoxaparin sodium
- Where
- 15 sites in United States, Australia and 13 more
- Sponsor
- Sanofi
Venous Thromboembolism, Deep Venous Thrombosis
Fixed Versus Weight-Based Enoxaparin Dosing in Thoracic Surgery Patients
The aim of this research is to better understand how patient-level factors can be used to predict the appropriate enoxaparin dose to maximize venous thromboembolism (VTE) risk reduction and minimize bleeding.
- Conditions
- Venous Thromboembolism, Deep Venous Thrombosis, Surgery
- Trial name
- NCT03251963
- Testing
- Fixed Dose Enoxaparin, Variable Dose Enoxaparin
- Where
- United States
- Volunteers
- 131 people
- Sponsor
- University of Utah
Non ST Segment Elevation Myocardial Infarction, Unstable Angina
Patients With High-risk Acute Coronary Syndrome Without ST-segment Elevation
This non-inferiority study aims at comparing Versa® to the reference enoxaparin (Clexane®, Sanofi-Aventis) in patients with high-risk unstable angina and NSTEMI.
- Trial name
- VECOR (NCT01356992)
- Testing
- Enoxaparin
- Where
- 5 sites in Brazil
- Volunteers
- 62 people
- Sponsor
- Eurofarma Laboratorios S.A.
Radial Artery Occlusion
Enoxaparin for Preventing the Radical Artery Occlusion After the Transradial Access Hepatic Arterial Infusion Chemotherapy
The present investigation is designed as a single-blind, randomized, controlled, bicentric trial. The objective is to ascertain whether the subcutaneous administration of enoxaparin sodium for prophylactic anticoagulation during…
- Trial name
- NCT06293287
- Testing
- Subcutaneous enoxaparin sodium
- Where
- China
- Volunteers
- 156 people
- Sponsor
- Zhongshan Hospital (Xiamen), Fudan University
Deep Venous Thrombosis, Pulmonary Embolus
Real-time Anti-Factor Xa Measurements in Surgical Patients to Examine Enoxaparin Metabolism and Optimize Enoxaparin Dose
Venous thromboembolism (VTE) encompasses deep venous thrombosis and pulmonary embolus, and is the proximate cause of death in over 100,000 hospitalized patients per year.
- Conditions
- Deep Venous Thrombosis, Pulmonary Embolus, Venous Thromboembolism
- Trial name
- NCT02704052
- Testing
- Real time enoxaparin dose adjustment, Standard enoxaparin dose
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- University of Utah
Kidney Disease
Safety Evaluation of Use Sodic Enoxaparin
The purpose of this study was to evaluate safety, not inferiority clinical and pharmacodynamic profile of the drug Enoxaparin Sodium produced by laboratory Blausiegel when compared with Clexane product, produced by Laboratory…
- Trial name
- Enoxaparin (NCT00673426)
- Testing
- Enoxaparin sodic
- Where
- Brazil
- Volunteers
- 60 people
- Sponsor
- Azidus Brasil
COVID-19, Deep Vein Thrombosis
Evaluating Dose Regimen of Intravenous Unfractionated Heparin and Low Molecular Weight Heparin in Critical Ill Patients Versus Critical Ill COVID-19 Patients Using Anti-Xa Levels.
To see whether our increased dosing regimen of unfractionated heparin (UF) and low molecular weight heparin (LMWH) in COVID-19 patients was effective at preventing thrombo-embolic complications.
- Conditions
- COVID-19, Deep Vein Thrombosis, Anticoagulants and Bleeding Disorders, Critical Illness
- Trial name
- NCT05224388
- Testing
- Enoxaparin, Heparin
- Where
- Belgium
- Volunteers
- 813 people
- Sponsor
- University Hospital, Ghent